Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant
Open Access
- 22 December 2020
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 21 (5), 1780-1788
- https://doi.org/10.1111/ajt.16427
Abstract
No abstract availableFunding Information
- National Institute of Allergy and Infectious Diseases (U01AI115714)
This publication has 30 references indexed in Scilit:
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdleHepatology, 2015
- Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 updateJournal of Hepatology, 2015
- Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfectionLiver Transplantation, 2012
- HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic TechnologiesCurrent HIV/AIDS Reports, 2011
- HBV and HIV Coinfection and Liver TransplantAmerican Journal of Transplantation, 2010
- Survival of Liver Transplant Patients Coinfected with HIV and HCV Is Adversely Impacted by Recurrent Hepatitis CAmerican Journal of Transplantation, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- The Survival Benefit of Liver TransplantationAmerican Journal of Transplantation, 2004
- A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis CHepatology, 2003